THURSDAY, Feb. 29, 2024 (HealthDay Information) — For sufferers with hematologic cancers, the percentages of growing extreme COVID-19 regardless of vaccination remained excessive by means of mid-2022, based on a research revealed on-line Feb. 23 in JAMA Community Open.
Sonia T. Anand, Ph.D., M.P.H., from the VA Boston Cooperative Research Program, and colleagues carried out a case-control research together with all sufferers with hematologic malignant neoplasms within the nationwide Veterans Well being Administration with extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an infection after vaccination. Sufferers with extreme COVID-19 (circumstances) versus nonsevere COVID-19 (controls) have been in contrast; information have been included for six,122 sufferers, 21.3 p.c of whom had extreme COVID-19.
The researchers discovered that the percentages of extreme illness have been increased in affiliation with age (adjusted odds ratio [aOR] per one-year improve, 1.05), therapy with antineoplastic or immune-suppressive medicine (e.g., together with glucocorticoids: aOR, 2.32), and comorbidities (aOR per comorbidity, 1.35). Booster vaccination was related to decrease odds of extreme illness. Total, 3.7 p.c of sufferers with SARS-CoV-2 an infection through the interval after oral antiviral medicine grew to become broadly utilized in March 2022 had development to extreme COVID-19.
“Though the magnitude of advantage of antiviral remedies throughout nonsevere illness couldn’t be quantified, the comparatively low proportion of handled sufferers who developed extreme COVID-19 is adequate to advertise higher use,” the authors write.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.